Once Daily Aminoglycoside Dosing: Maintained Efficacy with Reduced Nephrotoxicity?

References

• Kunin CM. Dosage schedules of antimicrobial agents. A historical review. Rev Infect Dis 1981; 3: 4–11
   PubMedGoogle Scholar
• Zhanel G G, Hoban D J, Harding G KM. The postantibiotic effect: A review of in-vitro and in-vivo data. DICP Ann Pharmacother 1991; 25: 153–163
   PubMedGoogle Scholar
• Van der Yourassowsky E, Linden M P, Crokaert F. One shot of high-dose amikacin: A working hypothesis. Chemother 1990; 36: 1–7
   Web of Science ®Google Scholar
• Zhanel G G, Karlowsky J A, Hoban D J, et al. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing curve method and the postantibiotic effect (PAE). Chemotherapy 1991; 37: 114–121
   PubMed Web of Science ®Google Scholar
• Blaser J, Stone B B, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in-vitro model. Antimicrob Agents Chemother 1985; 27: 343–349
   PubMed Web of Science ®Google Scholar
• Blaser J, Stone B B, Groner M C, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergency of resistance. Antimicrob Agents Chemother 1987; 31: 1054–1060
   PubMed Web of Science ®Google Scholar
• Moore R D, Lietman P S, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–99
   PubMed Web of Science ®Google Scholar
• Hatala M, Moravek J, Prat V, et al. Daily single dose gentamicin therapy in experimental pyelonephritis. Infection 1977; 5: 232–235
   PubMed Web of Science ®Google Scholar
• Powell S H, Thompson W L, Luthe MA. Once-daily versus continuous aminoglycoside dosing. Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis 1983; 147: 918–932
   PubMed Web of Science ®Google Scholar
• Pechere M, Letarte R, Pechere JC. Efficacy of different dosing schedules of tobramycin for treating a murine klebsiella bronchopneumonia. J Antimicrob Chemother 1987; 19: 487–491
   PubMed Web of Science ®Google Scholar
• Kapusnik J E, Hackbarth C J, Chambers H F, et al. Single large daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988; 158: 7–12
   PubMed Web of Science ®Google Scholar
• Wood C A, Norton D R, Kohlhepp SJ. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22
   PubMed Web of Science ®Google Scholar
• Herscovici L, Grise G, Thauvin C. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis 1988; 20: 205–212
   PubMed Web of Science ®Google Scholar
• Gerber A U, Kozak S, Segessenman C, et al. Once daily versus thrice daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 1989; 8: 233–237
   PubMed Web of Science ®Google Scholar
• Labowitz E, Levison M E, Kay D. Single dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465–470
   PubMed Web of Science ®Google Scholar
• Klastersky J, Prevost J M, Meunier-Carpentier F, et al. Comparative trial of single-dose versus twice daily sisomicin in bacteriuric patients. J Clin Pharmacol 1977; 17: 520–528
   PubMed Web of Science ®Google Scholar
• Shankar A, Sharma SD. Gentamicin as once daily dose therapy in recurrent urinary tract infections in children. Cur Ther Res 1987; 41: 599–603
   Web of Science ®Google Scholar
• Fan S T, Lau W Y, Tech-Chan C H, et al. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69–74
   PubMed Web of Science ®Google Scholar
• Mailer R, Isaksson B, Nilsson L, et al. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988; 22: 75–79
   PubMed Web of Science ®Google Scholar
• Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: Single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–937
   PubMed Web of Science ®Google Scholar
• Hollender L F, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patient with appendicitis with other intra-abdominal infections. J Antimicrob Chemother 1989; 23: 773–783
   PubMed Web of Science ®Google Scholar
• De Vries P J, Verkooyen R P, Leguit P, et al. Prospective ramdomized study of once-daily versus thrice-daily netilmicin regimens in patients with intra-abdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161–168
   PubMed Web of Science ®Google Scholar
• Ter Braak E W, De Vries P J, Bouter K P, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 58: 58–66
   Google Scholar
• Tulkens PM. Experimental studies on nephrotoxicity of aminoglycosides at low doses. Am J Med 1986; 80: 105–114, suppl 6B
   PubMed Web of Science ®Google Scholar
• Laurent G, Carlier M B, Rollman B, et al. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with gentamicin and amikacin. Biochem Pharamacol 1982; 31: 3861–3870
   PubMed Web of Science ®Google Scholar
• Guliano R A, Paulus G J, Verpooten G A, et al. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int 1984; 26: 838–847
   PubMed Web of Science ®Google Scholar
• Kaloyanides G J, Pastoriza-Munoz E. Aminoglycoside nephrotoxicity. Kidney Int 1980; 18: 571–582
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Clerckx-Braun F, Ph Jacqmin, et al. Effect of schedule of aminoglycosides administration on urinary phospholipids excretion. Renal Failure 1989–90; 11(4)250
   Google Scholar
• Mutti A, Lucertini S, Valcavi P, et al. Urinary excretion of brush-border antigen revealed by monoclonal antibody: Early indicator of toxic nephropathy. Lancet 1985; 2: 914–916
   PubMed Web of Science ®Google Scholar
• Meyer RD. Risk factors and comparison of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80: 119–125, suppl 6B
   PubMed Web of Science ®Google Scholar
• Appel GB. Aminoglycoside nephrotoxicity: physiologic studies of the sites of nephron damage. The Aminoglycosides: Microbiology, Clinical Use, and Toxicology, A Whelton, HC Neu. Dekker, New York 1982; 269–282
   Google Scholar
• Parker R A, Bennett W M, Porter GA. Animal models in the study of aminoglycoside nephrotoxicity. The Aminoglycosides: Microbiology, Clinical Use, and Toxicology, A Whelton, HC Neu. Dekker, New York 1982; 235–267
   Google Scholar
• Morin J P, Viotte G, Vandewalle A, et al. Gentamicin-induced nephrotoxicity: A cell biology approach. Kidney Int 1980; 18: 583–590
   PubMed Web of Science ®Google Scholar
• Reiner N E, Bloxham D D, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978; 4: 85–101, suppl A
   PubMed Web of Science ®Google Scholar
• Bennett W M, Plamp C E, Gilbert D N, et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–580
   PubMed Web of Science ®Google Scholar
• Sackett DL. Rules of evidence and clinical recommendations of the use of antithrombotic agents. Chest 1989; 95: 2–4, suppl
   PubMed Web of Science ®Google Scholar
• Bourke G J, Daly L E, McGilvray J. Interpretation and Uses of Medical Statistics3rd ed. Blackwell Scientific Publ, Oxford 1985; 313–314
   Google Scholar